As a result of the t(11;22)(q24;q12) chromosomal translocation characterizing the Ewing family of tumors (ET), the amino terminal portion of EWS, an RNA binding protein of unknown function, is fused to the DNA-binding domain of the ets transcription factor Fli1. The hybrid EWS-Fli1 protein acts as a strong transcriptional activator and, in contrast to wildtype Fli1, is a potent transforming agent. Similar rearrangements involving EWS or the highly homologous TLS with various transcription factors have been found in several types of human tumors. Employing yeast twohybrid cloning we isolated the seventh largest subunit of human RNA polymerase II (hsRPB7) as a protein that speci®cally interacts with the amino terminus of EWS. This association was con®rmed by in vitro immunocoprecipitation. In nuclear extracts, hsRPB7 was found to copurify with EWS-Fli1 but not with Fli1. Overexpression of recombinant hsRPB7 speci®cally increased gene activation by EWS-chimeric transcription factors. Replacement of the EWS portion by hsRPB7 in the oncogenic fusion protein restored the transactivating potential of the chimera. Our results suggest that the interaction of the amino terminus of EWS with hsRPB7 contributes to the transactivation function of EWS-Fli1 and, since hsRPB7 has characteristics of a regulatory subunit of RNA polymerase II, may in¯uence promoter selectivity.
Introduction
Speci®c chromosomal translocations have been observed in leukemia, lymphoma and in several types of sarcoma. In many cases gene rearrangements associated with these neoplasms result in structural alteration of transcription factors (Rabbitts, 1994) . The t(11;22)(q24;q12) translocation observed in 85% of the Ewing family of tumors (ET), results in fusion of the EWS gene with the ets family transcription factor gene Fli1 (Turc Carel et al., 1983; Delattre et al., 1992; Aurias et al., 1983) . The EWS-Fli1 fusion gene codes for a chimeric protein in which the amino terminal moiety of EWS, which is rich in glutamine, serine and tyrosine residues, is fused to the carboxy-terminal DNA-binding domain (ets domain) of Fli1 (Delattre et al., 1992) . EWS was the ®rst member of a growing family of RNA-binding proteins, including TLS/FUS (Zinszner et al., 1994; Rabbitts et al., 1993; Crozat et al., 1993) , hTAF II 68 (Bertolotti et al., 1996) , the snRNP associated 69 KD protein (Hackl and Luhrmann, 1996) , the bovine Pigpen protein (Alliegro and Alliegro, 1996) and Drosophila Cabeza/SARFH (Stolow and Haynes, 1995; Immanuel et al., 1995) , that share distinct structural characteristics in their carboxy termini, such as an RNP motif, RGG boxes and a putative zinc-®nger domain. However, its biological functions largely remain elusive.
In contrast to germline Fli1, overexpression of EWSFli1 promotes transformation of murine ®broblasts (NIH3T3) and induces tumors in nude mice (May et al., 1993; Lessnick et al., 1995) , and recombinant antagonists to EWS-Fli1 interfere with tumor cell growth in vitro and in vivo (Ouchida et al., 1995; Kovar et al., 1996) suggesting that it plays an essential role in tumor etiology. Both the EWS portion and the Fli1 domain of the chimeric protein are essential for transformation (Bailly et al., 1994) .
Replacement of the normal transcription activation domain of Fli1 by EWS converts the nontransforming gene Fli1 into the transforming gene EWS-Fli1. The fact that EWS-Fli1 is a more potent transcriptional activator than Fli1 and is constitutively expressed in ET, led to the suggestion that EWS-Fli1 mediated transformation may be due to unscheduled activation or repression of genes normally regulated by Fli1 or similar ets proteins May et al., 1993; Bailly et al., 1994) .
In a subset of ET the EWS gene is rearranged with other members of the ets family, including the ERG gene on chromosome 21 (Zucman et al., 1993b; Sorensen et al., 1994) , FEV on chromosome 2 (Peter et al., 1997) and the more distantly related ets genes ETV1 and E1A-F (ETV4) on chromosomes 7 and 17, respectively (Jeon et al., 1995; Urano et al., 1996) . Fusions of EWS to other families of transcription factors have been observed in dierent types of tumors, including CHOP in myxoid liposarcoma (Panagopoulos et al., 1996) , ATF-1 in malignant melanoma of soft parts (Zucman et al., 1993a; Fujimura et al., 1996) , WT1 in intra-abdominal desmoplastic small round cell tumor (Ladanyi and Gerald, 1994) and to orphan nuclear receptors in myxoid chondrosarcoma (Labelle et al., 1995; Clark et al., 1996) . TLS/FUS-CHOP and TLS/FUS-ERG chimeras have been described in myxoid liposarcoma (Rabbitts et al., 1993; Crozat et al., 1993) and acute myeloid leukemia (Panagopoulos et al., 1994; Ichikawa et al., 1994) , respectively. All these gene rearrangements result in the fusion of the amino terminal portions of EWS or TLS/FUS to DNA-binding proteins, further suggesting that disruption of transcriptional control contributes to their transforming potential.
There is evidence that the mechanism of EWS-Fli1 mediated gene activation and/or speci®c protein-protein interactions between chimeric EWS proteins and unknown cellular targets are important for transformation. Fusions of the DNA-binding domain of Fli1 to other activation domains did not always result in transforming proteins (Lessnick et al., 1995) , and sequential deletion of the EWS domain of EWS-Fli1 revealed that the amino terminal peptide repeats of EWS play a more critical role in transformation whereas the carboxy terminal amino acids mainly contribute to transcriptional activation (Lessnick et al., 1995) .
In an attempt to gain insight into the mechanism of transactivation and transformation activities of EWSFli1, we were interested in cellular proteins which speci®cally interact with the EWS amino terminus. We employed the yeast two-hybrid system (Fields and Song, 1989) to screen a human T-cell derived cDNA library for proteins that associate with an amino terminal peptide of EWS. Here, we demonstrate speci®c association of hsRPB7, the seventh largest subunit of human RNA polymerase II, with EWS-Fli1 in vitro and in vivo. Furthermore, our data also provide evidence that the interaction between EWS-Fli1 and hsRPB7 may play a role in activation of target genes by EWS-Fli1.
Results

Cloning of hsRPB7 by the yeast two-hybrid screen
A yeast two-hybrid screen was performed to identify proteins that interact with the amino terminus of EWS. The two hybrid system is based on the functional reconstitution of a transcriptional activator, such as the yeast GAL4 protein (Fields and Song, 1989) . The amino terminal portion of EWS is a strong transcriptional activator when fused to a DNA-binding domain and, when combined with the Fli1 ets domain, mediates transformation of NIH3T3 cells May et al., 1993) . The region required for minimal transactivating but full transforming activity was previously narrowed down to EWS amino acids 1 ± 82 (Lessnick et al., 1995) . A bait expression vector was constructed by fusing essentially the amino terminal 82 amino acids of EWS to the GAL4 DNAbinding domain (pGBT-EWS D82 ± 246 ). This bait plasmid was transformed into HF7c indicator cells generating HF7c-DEWS; this strain displayed minimal growth in the absence of histidine and showed acceptable weak bgalactosidase activity, con®rming low gene activitation by the EWS-GAL4 hybrid in yeast.
HF7c-DEWS cells were transformed with a T-cell cDNA library which expressed proteins as fusions with the GAL4 transactivation domain (Durfee et al., 1993) , and spread on selective medium lacking leucine, tryptophan and histidine. 114 histidine prototroph clones were obtained from 7.5610 5 transformants screened. 85 his + colonies were also b-galactosidase positive. To eliminate false positives, cells were allowed to lose their EWS bait plasmids and were subsequently retransformed with control heterologous baits. GAL4/ cDNA library plasmids that showed speci®c interaction with EWS in yeast were rescued by transformation into E. coli for further analysis.
One clone was found to contain a full length cDNA encoding hsRPB7, the seventh largest subunit of human RNA polymerase II (Khazak et al., 1995) . Figure 1 shows that in yeast, hsRPB7 speci®cally bound to EWS and did not interact with the GAL4 DNA-binding domain (pGBT9) or the extraneous protein lamin C (encoded in pLAM5'). Conversely, EWS bound to hsRPB7 and not to the GAL4 activation domain (pACT).
EWS-Fli1 associates with hsRPB7 in vitro and in vivo
To test whether the interaction between EWS and hsRPB7 was direct or was mediated by a third unidenti®ed yeast component, we investigated the association of the in vitro translated proteins. EWSFli1 and 35 S-methionine-labeled hsRPB7 polypeptides were incubated for 1 h at 48C and were subsequently immunoprecipitated with an antibody speci®c for the carboxy terminus of Fli1. Labeled hsRPB7, but not a control protein of a similar size (human Dad1), was coimmunoprecipitated with EWS-Fli1 (Figure 2 , lanes 1 and 2).
Next, we sought to examine the association of EWSFli1 and hsRPB7 in vivo. Nuclear extracts were prepared from four dierent cell lines: IARC-EW2 and SK-ES1 are both Ewing tumor cell lines expressing EWS-Fli but not Fli1; MOLT4, a lymphoblastic leukemia cell line, does not contain EWS-Fli1 but expresses germline Fli1; and the neuroblastoma cell line Vi856 is negative for both gene products as determined by RNA and protein analyses, including immunoprecipitation with the Fli1 speci®c antibody (data not shown).
EWS-Fli1 and Fli1 were speci®cally precipitated from nuclear extracts using anti-Fli1 antibody (not shown). After thorough washing, bound proteins were subjected to Western blot analysis with an antiserum raised against hsRPB7 (Khazak et al., 1995) .
Although hsRPB7 was present in all cell lines at similar levels ( Figure 2 , lanes 3 ± 6), it was speci®cally Figure 1 RPB7 binds speci®cally to EWS in the yeast two hybrid system. HF7c cells were transformed with the indicated plasmids and equal amounts of three independent colonies were tested for b-galactosidase activity in a ®lter assay
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R Petermann et al coprecipitated from Ewing tumor nuclear extracts (lanes 9 and 10) but neither from neuroblastoma cells (lane 7) nor from wildtype Fli1 expressing lymphoblastic cells (lane 8). These data indicate that hsRPB7 binds to EWS-Fli1 in vivo and that this association depends on the EWS portion of the fusion protein.
In contrast, when precipitating with an antibody against the carboxy terminal portion of EWS, which is replaced by the ets domain in the oncogenic fusion proteins, no association between hsRPB7 and germline EWS was observed ( Figure 3 ).
Overexpression of hsRPB7 increases the transactivating ability of EWS-Fli1 but not of Fli1
Since hsRPB7 is a subunit of RNA polymerase II and thus is part of the transcription machinery (Khazak et al., 1995) it is tempting to speculate that this interaction may play a role in the transcription activation potential of EWS-Fli1. To test this hypothesis, we sought to determine the in¯uence of hsRPB7 overexpression on the transcriptional activation potential of EWS-Fli1 and germline Fli1. Expression of hsRPB7, EWS-Fli1 and Fli1 was accomplished by inserting the corresponding full length cDNAs into the CMV promoter based vector pCMVNeo (Baker et al., 1990) resulting in pCMV-RPB7, pCMV-Sta7 and pCMV-Fli1, respectively. Transcription activation was tested by the ability of EWS-Fli1 and Fli1 to transactivate the chloramphenicol acetyl transferase gene (CAT) from the E74 ets protein binding sequence May et al., 1993; Bailly et al., 1994) in the reporter plasmid pCAT-3E74 (Kovar et al., 1996) . We co-transfected mouse ®broblast cells (NIH3T3) with the reporter plasmid, EWS-Fli1 or Fli1 expression vectors and increasing amounts of hsRPB7 expression plasmid. Cells were incubated for 48 h and lysates were assayed for CAT activity. As shown in Figure 4a , EWS-Fli1 transactivated the CAT gene (lane 2) but a strikingly higher activation was achieved when increasing amounts of hsRPB7 expression vector were included (lanes 3 to 6). Wildtype Fli1 was also able to stimulate CAT expression from pCAT-3E74, but in contrast to EWS-Fli1, this activity was not aected by the addition of hsRPB7. Similarly, hsRPB7 synergized with a recombinant GAL4-EWS fusion on a GAL4 responsive promoter in NIH3T3 cells (Figure 4b ). No activation of reporter genes was observed by transfection of pCMV-RPB7 only at all concentrations tested (Figure 5b , lane 7 and data not shown).
Fusion of hsRPB7 to the DNA-binding domain of Fli1 results in a potent activator of transcription
The above results suggest that the amino terminus of EWS-Fli1 may in¯uence gene activation by formation of a physical link to RNA polymerase II. To test whether the interaction between these two proteins would be sucient to activate transcription, we constructed recombinant chimeras between hsRPB7, replacing the ESW moiety and Fli1 and assayed their ability to activate a reporter gene in NIH3T3 cells.
The Fli1 portion of EWS-Fli1 type I (amino acids 221 ± 452), including the 3'-ets domain, was fused carboxy terminally to full length hsRPB7 in pCMVNeo (pCMV-RPB7-Fli1) (Figure 5a ). Figure 5b shows that in cotransfection with pCAT-3E74 RPB7-Fli1 activated expression of the reporter gene comparable to EWS-Fli1 in NIH3T3 cells (lanes 2 and 3). Consistent with previous reports Ohno et al., 1993 ) the Fli1 moiety alone (amino acids 221 ± 452 in pCMV-Fli221-452) was also able to activate transcription but at a considerably lower level as compared to RPB7-Fli1 (lane 4). In contrast to the ®ndings by Ohno et al. (1993) for truncated germline and chimeric Fli1 proteins, deletion of the Fli1 carboxy terminal transcriptional activation domain did not aect gene activation properties of either the RPB7-Fli1 fusion or its Fli1 portion only (lanes 5 and 6).
The fact that hsRPB7 is part of the polymerase suggests that RPB7-Fli1 interacts with components of the transcription machinery via its RPB7 moiety. If this communication is necessary, RPB7-Fli1 mediated transcriptional activation will be completed by overexpression of ectopic hsRPB7. Figure 5c shows that increasing amounts of cotransfected hsRPB7 markedly reduced transactivation by RPB7-Fli1. This eect cannot be explained as a general squelching eect of hsRPB7, since no in¯uence of increasing hsRPB7 concentration on transactivation by germline Fli1 was observed (Figure 4b ). These results support the idea that tethering of hsRPB7 to DNA can promote transcription suggesting that association between hsRPB7 and EWS-Fli1 may play a role in the transactivation potential of the chimeric oncoprotein. 
Discussion
In order to further characterize the role of EWS-Fli1 fusion proteins in transformation and gene activation we sought to clone proteins interacting with the amino terminus of EWS. By the means of the yeast twohybrid interaction trap we identi®ed hsRPB7, the seventh largest subunit of human RNA polymerase II, as one potential partner of EWS and con®rmed this association in vitro and in ET nuclear extracts by coimmunoprecipitation. In reporter gene assays we demonstrated that hsRPB7 stimulates speci®cally EWS-Fli1 mediated gene activation. Direct fusions of hsRPB7 with the Fli1 DNA-binding domain, replacing the EWS portion, were also able to promote transcriptional activation, and this activity could not solely be attributed to the Fli1 domain. Taken together, these results support the idea that the amino terminus of EWS-Fli1 binds to hsRPB7 and that this association could aect transcriptional activation. A similar physical interaction of hsRPB7 has recently been observed with an unrelated transcription factor (human retinoic acid receptor-a) (Shemshedini et al., submitted). We did not observe interaction between germline Fli1 and hsRPB7, and overexpression of hsRPB7 did not in¯uence Fli1 stimulated transcription, indicating that hsRPB7 does not generally boost gene activation. The speci®c association of EWS-Fli1 but not of Fli1 with hsRPB7 may thus de®ne a dierence in the mechanism of gene activation between these two transcription factors. This distinction is of particular interest since hsRPB7 has some characteristics of a regulatory factor in RNA polymerase II transcription. In yeast, RPB7 together with RPB4 forms a subcomplex of RNA polymerase II that may exert functions similar to prokaryotic sigma factors. In RNA polymerase II preparations from rapidly dividing yeast cells approximately 20% of the enzyme is found to contain all 12 subunits, whereas 80% lack subunits 4 and 7 (Edwards et al., 1991) . As cells reach stationary phase virtually all Pol II contains the RPB4-RPB7 complex (Choder and Young, 1993) . Yeast strains lacking RPB4 rapidly lose viability accompanied by a decline in mRNA synthesis in response to thermal and nutrient stress, suggesting that the RPB4/7 complex exerts functions analogous to the stress speci®c prokaryotic sigma factors. In vitro the subunit 4/7 complex is required for promoter recognition but not for chain elongation, however, this subcomplex is not sucient for speci®c transcription initiation and can be partially supplanted by an activator protein (Edwards et al., 1991) . Although several genetic and biochemical data including rescue of lethal yeast rpb7 deletions by the wildtype human homologue suggest a high degree of functional conservation between yeast and human RPB7 proteins, it was demonstrated recently that yeast RPB7, in contrast to hsRPB7, completely failed to interact with hsRPB4 (Khazak et al., 1998) . The fusion between the EWS amino terminus and the GAL4 DNAbinding domain only weakly stimulated transcription in yeast, an essential prerequisite for our two-hybrid screen. Therefore, it remains to be established if yeast RPB7 is able to interact with human EWS. In murine ®broblasts, the amino terminal 82 amino acids of EWS, when fused to the GAL4 DNA binding domain, have previously been shown to display only minimal transactivation properties and in context with Fli1 to retain almost full transformation activity (Lessnick et al., 1995) . These data indicate that additional interactions with components of the transcription machinery or transcription factors might be necessary for the high transactivation potential of EWS-Fli1. We know from virion protein VP16 that a single strongly activating domain can contact four dierent transcription factors (Xiao et al., 1994; Stringer et al., 1990; Lin et al., 1991; Goodrich et al., 1993) . Since the EWS amino terminus is largely composed of a degenerate repeated peptide motif we cannot exclude that there are several interfaces contacting hsRPB7 downstream of the ®rst 82 amino acids. It is tempting to speculate that the interaction of EWS-Fli1 with hsRPB7 may play a role in the high transformation activity of the EWS amino terminus. Fine mapping of the interaction sites in both proteins and modulation of the strength of association, together with the analysis of the interdependence of hsRPB7 expression level and transformation eciency may determine the role of EWS-Fli1-hsRPB7 interaction in transformation.
A major concern is if germline EWS, which is present at much higher levels than EWS-FLI1 in the tumor cells, also contacts hsRPB7. In experiments using a carboxy terminus-speci®c antibody to precipitate germline EWS we were unable to see selective coprecipitation of hsRPB7. In accordance with our ®ndings, Tora and coworkers demonstrated recently that only trucated EWS proteins lacking the Cterminus, as is the case in chimeric EWS-FLI1 molecules, were able to associate with hsRPB7 (Bertolotti et al., 1998) . Presumably, fusion to Fli1 causes as structural change of the amino terminal EWS domain making it accessible for interaction with hsRPB7. Thus it is unlikely that EWS competes with EWS-FLI1 for hsRPB7 interaction.
Although the exact functions of germline EWS and its relatives remain largely unknown, a growing body of evidence suggests that they are involved in mRNA transcription. Speci®cally hTAF II 68 and TLS have recently been shown to localize within the TFIID complex and evidence obtained by Tora and coworkers favours the idea that EWS can also be found as part of this general transcription factor (Bertolotti et al., 1996) . However, in contrast to germline EWS, EWS-Fli1 does not appear to be stably associated with high molecular weight TFIID and RNA polymerase II complexes (Bertolotti et al., 1998) . In concordance with Bertolotti's ®ndings, hsRPB7 was the only component of these transcription factors cloned in our two hybrid screen using the EWS amino terminus as a bait. Considering EWS as a bona ®de TAF II one may speculate that EWS-Fli1 aects transcription activation at two dierent stages: The amino terminal moiety of EWS-Fli1 contacts components of TFIID and triggers formation of the initiation complex while binding to hsRPB7 assists entry of the RNA polymerase II. We need, however, to elucidate the entire network of protein-protein interactions involving EWS to exactly de®ne its role in gene activation. On the basis of our and Bertolotti's combined results it is intriguing to speculate that the ET speci®c chimeric EWS protein may expose a unique and functionally essential epitope at its aminoterminus that may serve as a speci®c target for future anti tumor agents.
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Materials and methods
Yeast two-hybrid interaction trap cloning
Strain HF7c (MATa, 112, , LYS : : GAL1-HIS3, URA3 : : [GAL4 17mers] 3 -CYCl-lacZ [Clontech Laboratories, Palo Alto, USA]) was transformed with pGBT9-EWSD82 ± 246 generating strain HF7c-DEWS which was maintained under selection for the TRPI + marker. HF7c-DEWS was transformed with the pACT-cDNA library (Durfee et al., 1993) and spread on his 7 , leu 7 , trp 7 selective media containing 30 mM 3-aminotriazole. After 5 days at 308C histidine prototroph clones were restreaked and single colonies were tested for b-galactosidase activity (Breeden and Nasmyth, 1985) . Positive (blue) clones were grown in leu 7 selective broth to allow for loss of pGBT-ESWD82 ± 246, approximately 200 cells were spread on leu 7 selective plates and after 3 days replicata-plated on SC-trp plates. Leu + , trp 7 , LacZ 7 colonies were retransformed with pGBT9, pGBT-EWSD82 ± 246, pLAM5' (Clontech Laboratories, Palo Alto, USA) or no plasmid and tested again for bgalactosidase activity. Library plasmids from clones that were positive only if they had been transformed with pGBT-EWSD82 ± 246 were recovered and transformed into E. coli HB101 cells.
Yeast techniques
Routine yeast growth and maintenance and plasmid isolation were done according to Guthrie and Fink (1991) . Yeast small scale transformation was performed as described by Ito et al. (1983) .
In vitro transcription/translation
The in vitro transcription reaction was performed using T7 RNA polymerase (Promega Corp., Madison, USA) with 25 ng/ml linearized template DNA according to the manufacturer's instructions. The RNAs were separated on a 5% acrylamide, 8 M urea gel, full length run o transcripts were cut out and eluted in 10 mM Tris/HCl pH 7.8, 1 mM EDTA. Translation reactions were performed in 40% rabbit reticulocyte extract (Promega Corp., Madison, USA), 40 ng/ml template RNA, 1 u/ml Rnasin 1 (Boehringer Mannheim, Germany), 10 nM amino acid mixture, 0.3 mCi/ml [ 35 S]methionine for 90 min at 308C. The reaction was stopped by adding 50 ng/ml RNaseA.
Preparation of nuclear extracts
The preparation of nuclei and nuclear extracts was performed essentially as described by Dignam et al. (1983) , except that the extracts were dialyzed against 300 ± 500 volumes of buer D (20 mM HEPES-KOH pH 7.9, 20% (v/v) glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethanesulfonyl¯uoride) for 5 h at 48C.
Immunocoprecipitation
In vitro translated proteins 25 ml of the translation reactions were mixed and incubated for 30 min at room temperature. 5 ml antiserum, raised against the carboxyterminal 93 amino acids of Fli1 (Zucman et al., 1993b) , were added and after incubation for 1 h at 48C complexed with Protein G-Sepharose. Matrices were washed at least six times with buer A (20 mM Tris/HCl pH 7.5, 75 mM KCl, 4 mM MgCl 2 , 0.5 mM EDTA pH 8.0, 1 mM dithiothreitol, 0.1% (v/ v) Tween 20, 12.5% (v/v) glycerol, 1 mM phenylmethanesulfonyl¯uoride). Proteins were eluted by boiling in sample buer containing sodiumdodecylsulfate and b-mercaptoethanol and subjected to denaturing 15% polyacrylamide gel electrophoresis.
Nuclear extracts 400 mg of nuclear extracts were incubated with Fli1-or EWS speci®c antibodies for 1 h at 48C. Protein G-Sepharose equilibrated in buer C250 (20 mM HEPES-KOH pH 7.9, 20% (v/v) Glycerin, 250 mM KCl, 0.05% Nonident-NP40, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM phenylmethane-sulfonyl¯uoride) were added and rotated at 48C for 45 min. Precipitations were washed at least six times with buer C250, resuspended in sample buer and separated on a 15% denaturing acrylamide gel.
Western blot
Denaturing protein gel electrophoresis and transfer to nitrocellulose membranes were performed essentially as described by Laemmli (1970) . Filters were incubated with primary antibodies (1 : 2000 in 0.5% v/w blocking solution), for 1 h at room temperature. Proteins were detected with peroxidase-labeled secondary antibodies and the chemoluminescent substrate luminol using BM Chemiluminescence Western Blotting Kit according to the manufacturer's instructions (Boehringer Mannheim, Germany).
Cell transfection and chloramphenicol acetyl transferase (CAT) assay
NIH3T3 cells were grown to 40 ± 60% con¯uence in medium containing 10% fetal calf serum and seeded at a density of 10 5 cells per well of a six-well plate. After 24 h RPMI1640 medium was replaced with Optimem1 medium and the cells were incubated with plasmid DNA/ Lipofectin 2 Reagent/Optimem1 mixture according to the manufacturers instructions (GibcoBRL, Gaithersburg, USA). After incubation for 24 h the transfection mixture was substituted by RPMI1640.
Forty-eight hours after transfection cells were harvested, resuspended in 50 ml 250 mM Tris-HCl pH 7.5 and subjected to three freeze-thaw cycles. Supernatants were heated at 658C for 5 min to inactivate potential inhibitors. CAT reactions were performed in the presence of 220 pmol acetyl coenzyme A (Pharmacia, Uppsala, Sweden) and 4 nmol 14 C-labeled chloramphenicol (51.5 mCi/mmol) (Du Pont, Belgium). The reactions were incubated at 378C for 5 h, extracted with ethylacetate and spotted onto TLC paltes (Merck, Darmstadt, Germany). Migration was accomplished in 95% chloroform/5% methanol.
Vector constructs
pGBT-EWS D82 ± 246 A cDNA fragment coding for the amino acids met1 to gln264 (corresponding to the EWS portion of the EWS-Fli1 type 1 fusion) was PCR-ampli®ed using pKS-Sta7 as template and oligonucleotides containing EcoRI and SalI restriction sites (sense and antisense primers, respectively) at their 5' ends. The PCR product was inserted into pGBT9/EcoRI ± SalI generating pGBT-EWS1 ± 264. The BamHI ± BglI fragment of pGBT-EWS1 ± 264 (coding for amino acids 82 ± 246) was removed, the ends were blunted (BamHI: Klenow; BglI: T4) and ligated.
pACT A vector coding for the GAL4 activation domain only, was generated by removing the insert of pACT-RPB7 and recircularization of the vector.
pGBT9 and pLAM5' Coding for the GAL4 DNA-binding domain (DBD) and a human lamin C-GAL4 DBD hybrid, respectively, were from Clontech Laboratories, Palo Alto, USA.
pKS-Sta7
Full length ESW-Fli1 type 1 cDNA cloned into pBluescript-KS + under control of the T7 promoter, kindly provided by O Delattre.
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pKS-RPB7 and pKS-DAD1 cDNAs containing the respective entire open reading frames were inserted into pBluescript II-KS + (Stratagene, La Jolla, USA) under control of the T7 promoter.
pCMV-Neo This plasmid was generated by excising the p53 insert from the BamHI site of pC53-SN3 (Baker et al., 1990) .
pCMV-KS The BssHII fragment of pBluescript II-KS + , containing the multiple cloning site, was inserted into the BamHI site of pCMV-Neo.
pCMV-Sta7
The EcoRI ± HindIII fragment of pKS-Sta7 (entire EWS-Fli1 type 1 cDNA) and pCMV-Neo linearized with BamHI were blunted with Klenow and ligated.
pCMV-RPB7 KpnI ± NotI fragment of pKS-RPB7 (hsRPB7 cDNA) was inserted into pCMV-KS/KpnI ± NotI.
pCMV-GAL4-EWS Fusion of GAL4-DBD to the amino terminal 264 amino acids of EWS. The HindIII/SalI fragment of pGBT-EWS1 ± 264 was blunted and inserted into the EcoRV site of pCMV-KS.
pCMV-RPB7-Fli1 Fusion of hsRPB7 to the Fli1 portion of EWS-Fli1 type 1. The cDNA of hsRPB7, coding for the entire protein was PCR ampli®ed using oligonucleotides rpb7+: 5'-GCGCGGATCCTCTGCCTGCCTACCT-GGTC and rpb77:5'-CGCCGTCGACTACAAGCCC-CAAGTAATCGTC (underlined bases indicate BamHI and SalI sites, respectively). The cDNA encoding amino acids 221 ± 452 of Fli1 was ampli®ed using primers¯i221+: 5'GCGC G T C G A C TATGACTCAGTCAGAAGAG-GAGC and¯i4527: 5'-GCGCGGATCCCTAGTAG-TAGCTGCCTAAGTGTG (underlined bases indicate SalI and BamHI sites, respectively). The cDNAs were fused in frame via SalI sites and inserted into pCMV-Neo/BamHI. pCMV-RPB7-FliDCTA Deletion of the carboxy terminal transcriptional activation domain of Fli1 (amino acids 269 ± 452) from RPB7-Fli1. Was constructed as pCMV-RPB7-Fli1 except that¯i3687: 5'-GCGTGGATCCT-TAAGCCTGGGCAATGCCGTG (underlined bases indicate BamHI site) was used as antisense primer in the ampli®cation of the Fli1 portion.
pCMV-Fli221-452 Fli1 moiety of EWS-Fli1 type 1. Oligonucleotides ews5'+: 5'-GCGCGGATCCGAGA-GAACGAGGAGGAAGGAGAG and ews5'7: 5'-GGCC-GCATGCCATTTTCTCTCCTTCCTCCTCGTT (underlined bases indicate BamHI and SphI site, respectively) were annealed and ®lled in to produce a double stranded DNA fragment containing bases 726 to the start codon of the EWS cDNA. The cDNA coding amino acids 221 ± 452 of Fli1 was ampli®ed using primers¯i-del+: 5'-CGCG-GCATGCCCTTCTTATGACTCAGTCAGAAGAGG and i452-(underlined bases indicate SphI site). Both fragments were fused in frame via SphI sites and ligated with pCMV-Neo/BamHI. pCMV-Fli221-368 Deletion of the carboxy terminal transcriptional activation domain from Fli221-452, was constructed as pCMV-Fli221-452, except that¯i3687 was used as antisense primer in the ampli®cation of the Fli1 moiety.
pCAT-3E74 Contains the bacterial gene for chloramphenicol acetyl transferase (CAT), SV40 promoter and three copies of the double stranded oligonucleotide GAA-TAACCGGAAGTAACTCTGCA (the core recognition sequence of ets proteins is underlined) harbouring the E74 binding site inserted in the PstI site of pCAT Promoter (Promega Corp., Madison, USA) (Kovar et al., 1996) . pGal4E1b TATA Reporter construct containing ®ve copies of a GAL4 responsive element in front of the CAT gene (Bailly et al., 1994) .
Cell lines
Cell lines IARC-EW2 (Ewing tumor) and Vi856 (neuroblastoma) were established by GM Lenior (International Agency for Research on Cancer, Lyon, France) and O Majdic (Institute for Immunology, University Vienna, Austria), respectively. SK-ES1 (Ewing's sarcoma, ATCC HTB 86), RD-ES (Ewing's sarcoma, ATCC HTB166), MOLT4 (acute lymphoblastic leukemia, ATCC CRL 1581) and NIH3T3 (mouse embryo ®broblasts, ATCC CCL 92) were from the American Type Culture Collection.
